Reducing the cost of friction: the need to keep talking Brendan Barnes Warsaw, 5 December 2007 Dialogue-Innovation-Future EFPIA CEE meeting May 2007.

Slides:



Advertisements
Similar presentations
GF8 – Vilnius, June 2007 Hugh Whittall Director Nuffield Council on Bioethics Establishing and supporting research ethics infrastructure and networking.
Advertisements

Good governance for water, sanitation and hygiene services
Building effective partnerships
Entrepreneurship and competitiveness for SMEs Dialogue between Brazil and the EU EU Enterprise and Innovation Initiatives Carl James.
Service user participation in clinical trials Partnership or Co-option? Dr. Jan Wallcraft Operational Manager of SURGE (Service User Research Group for.
Toebes, May 2010 Human rights, health sector commercialisation and corruption Dr Brigit Toebes, The University of Aberdeen School of Law
Help inform our response to Monitor’s consultations on procurement, patient choice and competition Guidance on “Section 75” regulations of the Health and.
How do we achieve cost effective cancer treatments in the UK? Professor Peter Littlejohns Department of Public Health and Primary Care.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Putting proportionality into practice A call for a more nuanced and mutual approach to university regulation Michael Gallagher.
Jane Jobarteh Midlands and East May 2013 The Future of Social Care Patients First and Foremost.
Workshop 501 and 505 Review barriers to communication
Chester Ellesmere Port & Neston Rural Making sure you get the healthcare you need Personal Health Budgets (PHB) Gus Cairns – Patient Leader, Being Well.
Policy recommendations for wider implementation of telemedicine Peeter Ross, MD, PhD e-Health expert, Estonian eHealth Foundation, Estonia.
ANNEXE 6. United Kingdom: Establishing a mixed economy in healthcare 2005 Duncan Innes Head of Public Policy.
School of Medicine & Health Setting the Scene: The Changing National Context David Hunter Professor of Health Policy & Management.
EU - JAPAN FTA Perspectives from the pharmaceutical industry EESC – Hearing on EU - Japan FTA Brussels, 15 January
Health care system in Belgium How Belgian patients can save 1 billion euro / year and the health insurance system 1,6 billion / year …
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Improving the competitiveness of the pharmaceutical industry Dominique Limet Senior Vice-President and Area Director Southern and Eastern Europe.
European Commission Dialogue-Innovation-Future An experience of the Pharmaceutical Forum Dr Stefaan Van der Spiegel, MD Competitiveness in the Pharmaceuticals.
Summing Up. Acknowledgments  Rapporteuring team  Presenters  Participants.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Training of Trainers Social Dialogue Construction Industry (ACTRAV) Werner Buelen, EFBWW Training of Trainers Social Dialogue Construction Industry (ACTRAV)
The Role of Patients in EU Policy Development European Health Forum Gastein October 2003 – Bad Gastein Presented by Erick Savoye Director of the European.
1 Richard Carter Head of Industry Sponsorship Department of Health London.
1 Case Study Innovative Medicines Initiative (IMI) Karen Strandgaard EFPIA EuroConference, Brussels April 26th, 2006.
Commissioning support for local authority sport and physical activity services c CLOA AGM 25 June 2015.
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
The future of commissioning 23 June 2015.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
Implementing national EHR strategies in Europe: organisational, social and political issues Laurence ESTERLE, MD,PhD INSERM U 750 ‘Medicine, Sciences,
The Dutch consultation economy in perspective | Communications | SER: an introduction Holland: man-made land Social dialogue finds its roots.
Holistic asset and strength based assessment March 2015 Facilitators George Topping Expert by Experience Allison Rosenthal Project Consultant Rose-Marie.
NHS England New Structure and Industry Engagement Richard Stubbs Head of Commercial and International Innovation NHS England.
PROCUREMENT & DISTRIBUTION INTEREST GROUP Autumn Symposium 2007
Fiscal Policy Audit – National Audit Office of Finland Hannu Rajamäki Director for Performance Audit NAO of Finland.
Social Care and Health working together 00A – 31 Jan LINks and Commissioning Janet Crampton National Commissioning Lead.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Funding and commissioning routes for public health 1 Healthy Lives, Healthy People Consultation on the funding and commissioning routes for public health.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
Access to Medicine Index Problem Statement Long-standing debate about: What is the role of the pharmaceutical industry in access to medicines? Where are.
Themes Emerging from Country and Related Presentations Notes from session 1545 – 1730 Thursday 17 February 2011 Albert Weale.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Social Care and Health working together 00D – Adult Social Care Adult Social Care A new direction 27 February 2006 Kathryn Hudson National Director for.
Enterprise Directorate General European Commission The EU Framework for a Competitive Pharmaceutical Industry for the Benefit of the Patient European.
The Dutch consultation economy: developments in social dialogue Véronique Timmerhuis.
Strengthening Social Dialogue in the Construction Industry National Seminars Latvia and Lithuania May 2006 Edited by Freek Thomasson.
1 Prevention, Reablement & Integration. 2 Background We are at an historic time for social care. We have a health and care system too focussed on crisis.
Single Competency Framework for Prescribers National Prescribing Centre (2012)
‘The right healthcare, for you, with you, near you’ Commissioning for Quality Deborah Fielding, Accountable Officer NHS Wiltshire CCG November 11 th 2015.
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
Balancing Value and Access to Innovative Medicines The HSE Experience.
The Organisation for Economic Co-operation and Development
Disclosure UK Talking about Transparency.
Health Technology Assessment
European-Comparative Effectiveness Research on online Depression Treatment E-COMPARED is funded by the European Community’s Seventh Framework.
WRHA Supply Chain Forum Presentation
Disclosure UK Talking about Transparency.
Partnership in the fight against poverty:
FamiliesUSA (healthcare) – Aims and Tactics
The Organisation for Economic Co-operation and Development
Pricing and Reimbursement of Medicines – European Practices
The European Anti-Corruption Report
David Moore European Center for Not-for-Profit Law
Andrea Sundstrand Associate Professor
Kaisa Immonen EPF Director of Policy
Principles of Effective Early Intervention
European Spallation Source ERIC Procurement
Presentation transcript:

Reducing the cost of friction: the need to keep talking Brendan Barnes Warsaw, 5 December 2007 Dialogue-Innovation-Future EFPIA CEE meeting May 2007

Different roles Common –Treatments for patient Differences –Industry – to make profit by delivering medicines and innovation –Governments – to provide high quality health care and manage budgets = Different roles – but still a relationship

Need to work together Dialogue is always useful Healthcare is one of the areas where dialogue is most important The challenges that you face are the mirror image of the ones we face The costs of failure are real –Time spent on arguing, appeals, political fights… –Lack of stability in policy –Rules are circumvented (loop-holes) or broken –Political interventions –Excessive lobbying activities

What is the dialogue about Innovation Cycle Healthcare provision funding Long-term relationship based on legitimate expectations

What is dialogue not about ? Corruption Weakening Government Easy wins Window-dressing

Golden rules Know the people (RESPECT) Understand their mandate, needs and long-term goals (ACCEPT) Negotiate (MEET) often Act in a predictable way (irrational behaviour is destructive)

Experience at both European and national levels, proves that the pharmaceutical industry is constructively contributing to healthcare policy and legislation debates.

Dialogue at national level UK: sophisticated systems put in place over a number of years through continuous dialogue. Belgium: Pharma.be participates in reimbursement commission France: innovation scale and criteria Sweden

Applied to pricing and reimbursement Advice to governments/payers Make sure industry understands your needs and goals Take the time to explain, consult and listen Accept comments from industry on policy and individual cases Transparency in documentation and process

What are the benefits ? Optimise Poland’s place in the innovation system Sustainable framework for policy (and business) Ability to discuss conflicts early Ability to identify areas of mutual benefit

Even if you are ”top dog”, it is worth getting it right